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Abstract: Pharmacologic treatments for Alzheimer’s disease include the cholinesterase 
inhibitors donepezil, galantamine, and rivastigmine. We reviewed their evidence by searching 
MEDLINE®, Embase, The Cochrane Library, and the International Pharmaceutical Abstracts 
from 1980 through 2007 (July) for placebo-controlled and comparative trials assessing cognition, 
function, behavior, global change, and safety. Thirty-three articles on 26 studies were included in 
the review. Meta-analyses of placebo-controlled data support the drugs’ modest overall beneﬁ  ts 
for stabilizing or slowing decline in cognition, function, behavior, and clinical global change. 
Three open-label trials and one double-blind randomized trial directly compared donepezil 
with galantamine and rivastigmine. Results are conﬂ  icting; two studies suggest no differences 
in efﬁ  cacy between compared drugs, while one study found donepezil to be more efﬁ  cacious 
than galantamine, and one study found rivastigmine to be more efﬁ  cacious than donepezil. 
Adjusted indirect comparison of placebo-controlled data did not ﬁ  nd statistically signiﬁ  cant 
differences among drugs with regard to cognition, but found the relative risk of global response 
to be better with donepezil and rivastigmine compared with galantamine (relative risk = 1.63 and 
1.42, respectively). Indirect comparisons also favored donepezil over galantamine with regard 
to behavior. Across trials, the incidence of adverse events was generally lowest for donepezil 
and highest for rivastigmine.
Keywords: Alzheimer’s disease, cholinesterase inhibitor, donepezil, galantamine, rivastigmine, 
systematic review, meta-analysis, indirect comparison
Introduction
Alzheimer’s disease is an age-associated neurodegenerative disorder, affecting approxi-
mately 24 million individuals worldwide (Hebert et al 2003). Primary manifestations 
of Alzheimer’s disease include cognitive impairment, alterations in behavior, and 
reduced ability to perform activities of daily living. Nonpharmacologic and phar-
macologic interventions are available, although none prevents or cures the disease. 
Non-pharmacologic interventions primarily address behavioral disturbances (eg, task 
simpliﬁ  cation, environmental modiﬁ  cation, minimal excess stimulation, etc) and other 
sources of cognitive impairment (eg, treating comorbid medical conditions, minimizing 
or eliminating drugs with deleterious cognitive side effects) (Cummings et al 2002). 
Pharmacologic therapies are intended to slow the progression of disease and improve 
symptoms. Drugs currently approved for Alzheimer’s include cholinesterase inhibitors 
(donepezil hydrochloride [donepezil], galantamine hydrochloride [galantamine], riv-
astigmine tartrate [rivastigmine], and tacrine hydrochloride [tacrine]) and memantine, 
an N-methyl-D-aspartate (NMDA) receptor antagonist.
Currently available drugs have demonstrated modest beneﬁ  ts, although their 
place in the treatment of Alzheimer’s disease has been heavily debated. For example, Clinical Interventions in Aging 2008:3(2) 212
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the American Psychiatric Association (2007) recommends 
the cholinesterase inhibitors donepezil, galantamine, and 
rivastigmine for mild to moderate Alzheimer’s disease, and 
suggests that they may be helpful for patients with severe 
disease. Memantine—a drug labeled for moderate to severe 
disease—is recommended for moderate to severe disease. In 
contrast, the National Institute for Clinical Excellence (NICE 
2007), an organization responsible for providing guidance 
to the UK’s National Health Service, only recommends 
donepezil, galantamine, and rivastigmine as options for the 
treatment of moderate Alzheimer’s disease. Memantine is 
not recommended unless it is being used as part of a clinical 
trial. Although NICE takes a relatively aggressive stance 
in comparison to other organizations inﬂ  uencing payment 
policy, the high cost and modest beneﬁ  ts of these drugs 
continue to raise concerns.
To date, numerous review articles have been published 
that summarize the clinical efﬁ  cacy and safety of drugs for the 
treatment of Alzheimer’s disease (Geldmacher 2003, 2007; 
Lanctot et al 2003a, 2003b; Trinh et al 2003; Masterman 
2004; Ritchie et al 2004; Forchetti 2005; Harry and Zakzanis 
2005; Kaduszkiewicz et al 2005; Birks 2006; Loveman 
et al 2006; Loy and Schneider 2006; Schmitt et al 2006; 
Takeda et al 2006; Beier 2007; Hansen et al 2007). Most 
reviews have focused on the second-generation cholinester-
ase inhibitors (ie, donepezil, galantamine, and rivastigmine), 
since they have largely supplanted the ﬁ  rst approved drug 
in this class (ie, tacrine) and are pharmacologically unique 
from memantine—a drug that targets glutamate rather than 
acetylcholine and has been studied primarily in more severe 
disease. These review articles can be differentiated by which 
speciﬁ  c drugs were included, the types of outcomes that 
were assessed, and by whether the focus was on overall 
efﬁ  cacy (eg, placebo-controlled trials) or on comparative 
efﬁ  cacy (eg, head-to-head trials or indirect comparison using 
placebo-controlled trials). A number of good-quality reviews 
have synthesized evidence regarding the overall efﬁ  cacy of 
donepezil, galantamine, and rivastigmine, although most 
focus exclusively on speciﬁ  c outcome domains rather than a 
broad spectrum of outcome measures. Additionally, reviews 
synthesizing comparative evidence are sparse, in large part 
because of the quality and quantity of head-to-head trials 
(Wilkinson et al 2002; Wilcock et al 2003; Jones et al 2004; 
Bullock et al 2005). Existing head-to-head evidence cannot 
be pooled because of signiﬁ  cant differences in trial popula-
tions and design, and only one review has attempted to make 
indirect comparisons using placebo-controlled data (Harry 
and Zakzanis 2005). Several other systematic reviews and 
meta-analyses have narratively compared effect sizes across 
drugs, acknowledging the potential limitations of making 
unadjusted indirect comparisons.
We conducted a systematic review and meta-analysis of 
donepezil, galantamine, and rivastigmine for the treatment of 
Alzheimer’s disease. We attempted to elaborate on previous 
review articles by including a broad spectrum of outcome 
measures (ie, cognition, function, behavior, and global 
assessment), and emphasizing comparative evidence. We 
made adjusted indirect comparisons using placebo-controlled 
data for outcome measures with sufﬁ  cient data.
Methods
Literature search
We searched MEDLINE®, Embase, The Cochrane Library, 
and the International Pharmaceutical Abstracts for studies 
addressing the general or comparative effectiveness of done-
pezil, galantamine, or rivastigmine for Alzheimer’s disease. 
Sources were searched from 1980 to 2007 (July) to identify 
literature relevant to the scope of our topic. We manually 
searched reference lists of relevant review articles and letters 
to the editor. Additionally, we hand-searched the US Center 
for Drug Evaluation and Research database and the National 
Institutes of Health clinical trials registry (www.clinicaltrials.
gov) to identify unpublished research.
Inclusion criteria
Results from randomized, controlled trials comparing 
one cholinesterase inhibitor to another or to placebo were 
included. Community dwelling and nursing home popu-
lations were eligible. Trials had to last at least 12 weeks 
and include at least one measure reﬂ  ecting the following: 
cognition, function, behavior, or clinical global assessment 
of change. Studies with statistically signiﬁ  cant baseline 
differences between treatment groups that were deemed to 
affect outcomes were excluded, as were studies with other 
fatal ﬂ  aws in study design or data analysis that contributed 
to a “poor” quality rating for internal validity. Compara-
tive trials were not required to be double-blinded because 
a priori we knew that the majority of evidence comes from 
open-label trials. Placebo-controlled trials were required to 
be double-blinded.
Quality assessment
We assessed the internal validity (quality) of trials based 
on predeﬁ  ned criteria developed by the US Preventive Ser-
vices Task Force (ratings: good, fair, or poor) (Harris et al 
2001) and the National Health Service Centre for Reviews Clinical Interventions in Aging 2008:3(2) 213
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and Dissemination (2001). Elements of internal validity 
assessment included, among others, randomization and 
allocation concealment, similarity of compared groups at 
baseline, use of intention-to-treat (ITT) analysis, and overall 
and differential loss to follow-up. Two independent reviewers 
assigned quality ratings; they resolved any disagreements by 
discussion and consensus or by consulting a third independent 
party. Trials that had a fatal ﬂ  aw in one or more categories 
were rated as poor quality and excluded from this analysis.
Data abstraction
Trained reviewers abstracted data from each study and 
assigned an initial quality rating; a senior reviewer read each 
abstracted article, evaluated the completeness of the data 
abstraction, and conﬁ  rmed the quality rating. We abstracted 
the following data from included trials: study design, 
eligibility criteria, intervention (drugs, dose, duration), addi-
tional medications allowed, methods of outcome assessment, 
population characteristics, sample size, loss to follow-up, 
withdrawals attributed to adverse events, results, and adverse 
events reported. We recorded ITT results if available.
Outcome measures
Measurement scales varied across studies. We grouped 
measurement scales according to the general domain being 
assessed: cognition, function, behavior, and global assess-
ment of change. We tried to limit outcome measures to a 
single measurement scale within each domain, although for 
some domains (eg, function), no single scale was used in 
the majority of trials so we abstracted data from most com-
monly used scales.
Cognition
We focused on the Alzheimer’s Disease Assessment Scale-
Cognitive section (ADAS-cog) as the primary measure 
of cognition (Rosen et al 1984). Higher scores on this 
11-question, 70-point scale reﬂ  ect more severe cognitive 
deﬁ  cits. Data were coded as the mean and standard deviation 
of the change from baseline to endpoint.
Function
Because measures of function are particularly variable 
among clinical trials, we included all of the following: the 
Alzheimer’s Disease Cooperative Studies Activities of Daily 
Living Inventory (ADCS/ADL); the Alzheimer’s Disease 
Functional Assessment and Change Scale (ADFACS); 
the Bristol Activities of Daily Living Scale (BADLS); the 
Caregiver-rated Modified Crichton Scale (CMCS); the 
Disability Assessment for Dementia (DAD); the Interview for 
Deterioration in Daily living activities in Dementia (IDDD); 
the Nurses Observation Scale for Geriatric Patients Activi-
ties of Daily Living subscale (NOSGER-IADL); and the 
Progressive Deterioration Scale (PDS). Functional outcome 
measures were initially coded as the mean and standard 
deviation of the mean change from baseline to endpoint for 
each measure, and later converted to a standardized effect 
size (Hansen et al 2007).
Behavior
Behavioral outcomes were limited to the Neuropsychiatric 
Inventory (NPI) (Cummings et al 1994), a 144-point scale, 
with higher scores reﬂ  ecting greater severity. Data were 
coded as the mean and standard deviation of the change from 
baseline to endpoint.
Global assessment of change
The Clinician Interview-Based Impression of Change Incor-
porating Caregiver Information (CIBIC+) scale was recorded 
as the primary global assessment of change (Knopman et al 
1994). The CIBIC+ includes a 7-point Likert scale to code 
the overall impression of change (“7” marked worsening; 
“4” no change; “1” marked improvement). This scale was 
coded as a binary outcome to classify responders (4) and 
nonresponders (4). The Clinical Global Impression of 
Change (CGI-C) was included as a secondary measure of 
global assessment of change (Schneider et al 1997). The 
CGI-C reﬂ  ects the same 7-point Likert scale as the CIBIC+, 
although it does not follow a semi-structured format with 
caregiver input. Both scales were coded as the number 
of responders and non-responders among participants 
randomized to each treatment.
Data synthesis
Head-to-head studies were described, but not quantitatively 
combined because there were too few studies and the major-
ity were open-label rather than double-blinded. Placebo-
controlled data were combined in meta-analysis for each 
outcome measure. For continuous data collected using the 
same measurement scale (eg, cognition and behavior), we 
conducted an analysis of the weighted mean difference. The 
weighted mean difference reﬂ  ects the difference in change 
from baseline to endpoint for active treatment compared with 
placebo, weighted by the inverse variance (ie, studies with 
smaller variance, and likely larger sample size, given more 
weight). For functional outcomes, which were assessed on 
a number of different measurement scales, we calculated Clinical Interventions in Aging 2008:3(2) 214
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a standardized mean difference (ie, standardized effect size). 
The standardized mean difference, sometimes referred to as 
d (Cohen 1988), is a scale-free measure of the separation 
between two group means. A standardized effect size of  “0” 
is comparable with no difference between active treatment 
and placebo. Global assessment of change was analyzed as 
the relative risk of being classiﬁ  ed as a responder for treat-
ment compared with placebo. Our primary analysis was 
limited to trials reporting the CIBIC+, although sensitivity 
analyses pooled data for the CIBIC+ and CGI-C.
All meta-analyses speciﬁ  ed a random effects model, 
which assumes that variability in effect sizes is due to 
sampling error plus unique differences in the set of true 
population effect sizes. We tested for heterogeneity of treat-
ment effects using the I2 statistic (Higgins et al 2003). To 
estimate possible publication bias caused by the tendency 
of published studies to be positive, we used funnel plots 
(Egger et al 1997).
Because no head-to-head evidence was available for 
the majority of drug comparisons, we conducted adjusted 
indirect comparisons of placebo-controlled trials employ-
ing the method proposed by Bucher and colleagues (1997). 
Adjusted indirect comparisons assess the relative beneﬁ  ts of 
two treatments when they have not been compared directly 
with each other, but have each been evaluated relative to a 
common comparator (Glenny et al 2005). Evidence suggests 
that indirect comparisons agree with head-to-head trials 
if component studies are similar and treatment effects are 
expected to be consistent in patients included in different tri-
als. For indirect comparisons of outcomes reﬂ  ecting continu-
ous data (eg, weighted mean difference), our reported values 
can be interpreted as the pooled weighted mean difference 
for Drug A minus the pooled weighted mean difference for 
Drug B. Values close to zero reﬂ  ect no differences between 
compared drugs. For binary data (eg, relative risk of global 
response), our reported values can be interpreted as the rela-
tive risk of responding with Drug B compared with placebo 
over the relative risk of responding with Drug A compared 
with placebo. Thus, overall relative risk values less than 
1.0 favor Drug A, while relative risk values greater than 1.0 
favor Drug B.
For completeness in assessing the beneﬁ  ts and risks of 
these drugs, we reviewed adverse events. Data from included 
trials were abstracted, and the mean incidence and 95% 
conﬁ  dence intervals (CI) for speciﬁ  c adverse events were 
calculated. The number of withdrawals, and the number 
of withdrawals due to adverse events, were recorded and 
summarized by drug. Meta-analysis was used to quantify 
the relative risk of withdrawing for each drug compared 
with placebo.
Results
We found 1,476 unduplicated citations (Appendix 1). Of 
these, 1,112 citations were excluded after reviewing the 
abstract and 321 full-text articles were retrieved. After full-
text review, 166 citations were excluded for failure to meet 
eligibility criteria, and 2 for poor methodological quality; 
120 citations were relevant for background information, 
and 33 articles on 26 studies were included in the review. A 
summary of included trials is shown in Table 1.
Placebo-controlled trials
Twenty-two placebo-controlled trials (27 articles) provided 
data for at least one prespeciﬁ  ed outcome measure (Rogers 
and Friedhoff 1996; Agid et al 1998; Corey-Bloom et al 
1998; Rogers et al 1998a, 1998b; Burns et al 1999; Rosler 
et al 1999; Homma et al 2000; Raskind et al 2000; Tariot 
et al 2000, 2001; Wilcock et al 2000; Feldman et al 2001; 
Mohs et al 2001; Rockwood et al 2001, 2006; Wilkinson 
and Murray 2001; Winblad et al 2001, 2006; Courtney 
et al 2004; Seltzer et al 2004; Brodaty et al 2005): 14 on 
cognition; 14 on function; 7 on behavior; and 13 on global 
assessment of change.
Cognition
Fourteen studies measured and reported the mean change in 
ADAS-cog score from baseline to endpoint for active treat-
ment compared with placebo; ﬁ  ve on donepezil (Rogers and 
Friedhoff 1996; Rogers et al 1998a, 1998b; Homma et al 
2000; Seltzer et al 2004); seven on galantamine (Raskind 
et al 2000; Tariot et al 2000; Wilcock et al 2000; Rockwood 
et al 2001, 2006; Wilkinson and Murray 2001; Brodaty et al 
2005); and two on rivastigmine (Corey-Bloom et al 1998; 
Rosler et al 1999). All of these studies lasted 3 to 6 months 
and included participants with mild to moderate dementia 
(except for one which included only participants with mild 
dementia; see Seltzer et al 2004). Across studies, the aver-
age age of participants was 74 years (range 69 to 78 years), 
and 62% were female (range 50% to 69% female). Limiting 
these studies to doses recommended in the manufacturers 
labeling (Figure 1), the pooled weighted mean difference 
in change between active treatment and placebo was −2.67 
(95% conﬁ  dence interval [CI] −3.28 to −2.06) for donepe-
zil, −2.76 (95% CI −3.17 to −2.34) for galantamine, and 
−3.01 (95% CI −3.80 to −2.21) for rivastigmine. The I2 
statistic—which reﬂ  ects the degree of heterogeneity among Clinical Interventions in Aging 2008:3(2) 215
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Table 1 Summary of included studies
Drug(s) Study Daily dosea Duration 
(weeks)
Baseline 
MMSE
Outcomeb Quality 
rating Cognition Function Behavior Global
Donepezil(D) vs. 
Galantamine(G)
Jones et al 2004 (D) 5–10 mg
(G) 8–24 mg
12 10–24 ADAS-cog DAD – – NAc
Wilcock et al 
2003
(D) 5–10 mg
(G) 16–24 mg
52 9–18 ADAS-cog BADLS NPI – NAc
Donepezil(D) vs. 
Rivastigmine(R)
Bullock et al 
2005
(D) 5–10 mg
(R) 3–12 mg
104 10–20 – ADCS/ADL NPI – Good
Wilkinson et al 
2002
(D) 5–10 mg
(R) 6–12 mg
12 10–26 ADAS-cog – – – NAc
Donepezil AD2000 Collab-
orative, 2004
5–10 mg 60 10–27 – BADLS NPI – Fair
Burns et al 1999 5–10 mgd 24 10–26 – IDDD – CIBIC+ Fair
Feldman et al 2001 5–10 mg 24 5–17 – DAD NPI – Good
Homma et al 
2000
5 mg 24 10–26 ADAS-Jcog CMCS – CGI-C Fair
Mohs et al 2001 10 mg 54 12–20 – ADFACS – – Fair
Rogers et al 1998a 5–10 mgd 12 10–26 ADAS-cog – – CIBIC+ Fair
Rogers et al 1998b 5–10 mgd 24 10–26 ADAS-cog – – CIBIC+ Fair
Rogers and 
Friedhoff 1996
5 mgd 12 10–26 ADAS-cog – – CGI-C Fair
Seltzer et al2004 10 mg 24 21–26 ADAS-cog – – – Fair
Tariot et al 2001 5–10 mg 24 5–26 – – – NPI Fair
Winblad et al 
2001
10 mg 52 10–26 – PDS – – Fair
Winblad et al 
2006
10 mg 24 1–10 – ADCS/ADL NPI CGI-C Fair
Galantamine Brodaty et al 2005e 16–24 mg 26 10–24 ADAS-cog ADCS/ADL NPI CIBIC+ Good
Raskind et al 
2000
24 mgd 24 11–24 ADAS-cog – – CIBIC+ Fair
Rockwood et al 
2001
24–32 mg 12 11–24 ADAS-cog DAD – CIBIC+ Fair
Rockwood et al 
2006
24 mg 16 10–25 ADAS-cog – NPI – Fair
Tariot et al 2000 16–24 mgd 20 10–22 ADAS-cog ADCS/ADL NPI – Fair
Wilcock et al 2000 24 mg 24 11–24 ADAS-cog DAD – CIBIC+ Good
Wilkinson and 
Murray 2001
18–24 mgd 12 13–24 ADAS-cog – – CGI-C Fair
Rivastigmine Agid et al 1998 6 mg 13 NRf – NOSGER – – Fair
Corey-Bloom 
et al 1998
6–12 mg 26 10–26 ADAS-cog PDS – CIBIC+ Fair
Rosler et al 
1999
6–12 mg 26 10–26 ADAS-cog PDS – CIBIC+ Fair
Notes: aFixed doses outside of the range of the manufacturer label excluded; ﬂ  exible dosing studies might allow doses outside of labeled range; bDoes not indicate whether 
the outcome was primary or secondary in the trial design, and some outcomes were not reported or abstracted; cNot applicable; open-label trials were not rated for quality; 
dValue reﬂ  ects ﬁ  xed dosing design (compared with ﬂ  exible dosing); eGalantamine and Galantamine Prolonged-Release Capsule (PRC); fDSM-III-R mild-to-moderate dementia.
Abbreviations: MMSE, Mini Mental State Exam; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive section; ADAS-Jcog, Japanese translation of ADAS-cog; SIB, Severe 
Impairment Battery; CGI-C, Clinical Global Impression of Change;  ADCS/ADL, Alzheimer’s Disease Cooperative Studies Activities of Daily Living Inventory; ADFACS, Alzheimer’s 
Disease Functional Assessment and Change Scale; BADLS, Bristol Activities of Daily Living Scale ; CMCS, Caregiver-rated Modiﬁ  ed Crichton Scale; DAD, Disability Assessment 
for Dementia; IDDD, Interview for Deterioration in Daily living activities in Dementia; NOSGER-IADL, Nurses Observation Scale for Geriatric Patients Activities of Daily 
Living; PDS, Progressive Deterioration Scale; CIBIC+, Clinician Interview-Based Impression of Change Incorporating Caregiver Information.Clinical Interventions in Aging 2008:3(2) 216
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pooled studies—was 0% for both donepezil and galantamine, 
but 70% for rivastigmine (reﬂ  ecting high heterogeneity for 
the two pooled studies). Pooled estimates were not statisti-
cally signiﬁ  cantly different when analyses were stratiﬁ  ed 
by dose (data not shown).
Function
Fourteen studies measured and reported the mean change 
from baseline to endpoint for active treatment compared with 
placebo for at least one measure of function; seven on done-
pezil (Burns et al 1999; Homma et al 2000; Feldman et al 
2001; Mohs et al 2001; Winblad et al 2001, 2006; Courtney 
et al 2004); four on galantamine (Tariot et al 2000; Wilcock 
et al 2000; Rockwood et al 2001; Brodaty et al 2005); and 
three on rivastigmine (Agid et al 1998; Corey-Bloom et al 
1998; Rosler et al 1999). Studies lasted from 3 months to 
more than 1 year and generally included participants with 
mild to moderate dementia (mean baseline MMSE = 18). 
One trial (Winblad et al 2006) included only participants 
with severe dementia (mean baseline MMSE = 6), who 
were more likely older and female than participants in other 
included studies. The standardized mean difference statisti-
cally signiﬁ  cantly favored active treatment for the majority 
of individual studies (Figure 2). The pooled standardized 
mean difference between active treatment and placebo was 
0.31 (95% CI 0.21 to 0.40) for donepezil, 0.27 (95% CI 0.18 
to 0.36) for galantamine, and 0.26 (95% CI 0.11 to 0.40) 
for rivastigmine. The I2 statistic was 0% for both donepezil 
and rivastigmine, and 26% for galantamine. No signiﬁ  cant 
publication bias was detected, and dose stratiﬁ  ed analyses 
did not statistically signiﬁ  cantly change overall conclusions 
(data not shown).
Behavior
Only seven studies measured and reported change in 
behavior using the NPI; four on donepezil (Feldman et al 
2001; Tariot et al 2001; Courtney et al 2004; Winblad et al 
2006); three on galantamine (Tariot et al 2000; Rockwood 
Figure 1 Meta-analysis of cognitive outcomes (ADAS-cog) for active treatment compared with placebo.
Notes: aLimited to doses recommended by product labeling.
Abbreviations: WMD, Weighted Mean Difference; PRC, Prolonged Release Capsule; CI, Conﬁ  dence Interval; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive 
section.
Drug Daily Doseª WMD
Donepezil
Homma et al., 2000 5mg -2.54 -3.84 to -1.24
Rogers et al., 1998a 5mg -2.50 -3.96 to -1.04
Rogers et al., 1998a 10mg -3.10 -4.56 to -1.64
Rogers et al., 1998b 5mg -2.49 -4.18 to -0.80
Rogers et al., 1998b 10mg -2.88 -4.57 to -1.19
Rogers & Friedhoff, 1996 5mg -3.20 -5.72 to -0.68
Seltzer et al., 2004 10mg -2.20 -4.07 to -0.33
Pooled -2.67 -3.28 to -2.06
Galantamine
Brodaty et al., 2005 16-24mg -2.80 -3.95 to -1.65
Brodaty et al., 2005 16-24mg (PRC) -2.50 -3.60 to -1.40
Raskind et al., 2000 24mg -3.90 -5.03 to -2.77
Rockwood et al., 2001 24-32mg -1.60 -2.70 to -0.50
Rockwood et al., 2006 16-24mg -2.15 -4.22 to -0.08
Tariot et al., 2000 16mg -3.10 -4.38 to -1.82
Tariot et al., 2000 24mg -3.10 -4.42 to -1.78
Wilcock et al., 2000 24mg -2.90 -4.00 to -1.80
Wilkinson & Murray, 2001 18mg -1.70 -4.07 to 0.67
Wilkinson & Murray, 2001 24mg -3.00 -5.61 to -0.39
Pooled -2.76 -3.17 to -2.34
Rivastigmine
Corey-Bloom et al., 1998 6-12mg -3.78 -4.92 to -2.64
Rosler et al., 1999 6-12mg -2.28 -3.39 to -1.17
Pooled -3.01 -3.80 to -2.21
-6 -5 -4 -3 -2 -1 1
Weighted Mean Difference (WMD) in ADAS-cog Change from Baseline to Endpoint
95% CI
0
Favors Active Treatment Favors PlaceboClinical Interventions in Aging 2008:3(2) 217
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et al 2001; Brodaty et al 2005); and none on rivastigmine. 
The pooled weighted mean difference in NPI score between 
active treatment and placebo was −4.3 (95% CI −5.95 
to −2.65) for donepezil and −1.44 (95% CI −2.39 to −0.48) 
for galantamine (Figure 3). Heterogeneity was moderate 
among pooled donepezil studies (I2 = 43%) and low among 
pooled galantamine studies (I2 = 0%). The moderate het-
erogeneity detected among donepezil studies likely was 
inﬂ  uenced by inclusion of the study by Winblad and col-
leagues (2006), which was limited to severe dementia. No 
signiﬁ  cant publication bias was detected, and dose stratiﬁ  ed 
analyses did not signiﬁ  cantly change overall conclusions 
(data not shown).
Global assessment of change
Nine studies reported the number of global responders 
(4) using the CIBIC+ structured interview; three on 
donepezil (Rogers et al 1998a, 1998b; Burns et al 1999); 
four on galantamine (Raskind et al 2000; Wilcock et al 
2000; Rockwood et al 2001; Brodaty et al 2005); and two 
on rivastigmine (Corey-Bloom et al 1998; Rosler et al 
1999). These studies lasted 3 to 6 months and included 
participants with mild to moderate dementia (mean age 
74 years, 63% female). The pooled relative risk of respond-
ing for active treatment compared with placebo (Figure 4) 
was 1.88 (95% CI 1.50 to 2.34) for donepezil, 1.15 (95% 
CI 0.96 to 1.39) for galantamine, and 1.64 (95% CI 1.29 to 
2.09) for rivastigmine. Heterogeneity was low among all 
pooled analyses (I2 = 0%). Funnel plots illustrated potential 
publication bias.
An additional four studies reported the number of global 
responders (4) using the CGI-C and were included in a 
sensitivity analysis (Homma et al 2000; Rogers and Friedhoff 
1996; Wilkinson and Murray 2001; Winblad et al 2006). 
These studies also lasted 3 to 6 months and compared with 
participants in trials measuring the CIBIC+, participants 
were similar with regard to baseline dementia severity, age, 
and gender. In sensitivity analyses, combining data for the 
CIBIC+ and the CGI-C did not signiﬁ  cantly inﬂ  uence the 
pooled estimates for donepezil or rivastigmine, but improved 
the pooled relative risk estimate for galantamine (RR = 1.21; 
95% CI 1.02 to 1.43). Additionally, combining ﬁ  xed doses to 
represent the overall number of active treatment responders 
for a given study did not alter conclusions.
Figure 2 Meta-analysis of functional outcomes for active treatment compared with placebo.
Notes: aLimited to doses recommended by product labeling.
Abbreviations: SMD, Standardized Mean Difference; PRC, Prolonged Release Capsule; CI, Conﬁ  dence Interval; ADCS/ADL, Alzheimer’s Disease Cooperative Studies Activities 
of Daily Living Inventory; ADFACS, Alzheimer’s Disease Functional Assessment and Change Scale; BADLS, Bristol Activities of Daily Living Scale; CMCS, Caregiver-rated Modiﬁ  ed 
Crichton Scale; DAD, Disability Assessment for Dementia; IDDD, Interview for Deterioration in Daily living activities in Dementia; NOSGER-IADL, Nurses Observation Scale 
for Geriatric Patients Activities of Daily Living; PDS, Progressive Deterioration Scale.
Drug Daily Doseª  SMD Scale
Donepezil
AD2000 Collaborative, 2004 5-10mg 0.17 -0.05 to 0.40 BADLS
Burns et al., 1999 5mg 0.18 -0.02 to 0.39 IDDD
Burns et al., 1999 10mg 0.22 0.02 to 0.43 IDDD
Feldman et al., 2001 5-10mg 0.58 0.35 to 0.82 DAD
Homma et al., 2000 10mg 0.34 0.08 to 0.60 CMCS
Mohs et al., 2001 10mg 0.37 0.17 to 0.58 ADFACS
Winblad et al., 2001 10mg 0.34 0.11 to 0.58 PDS
Winblad et al., 2006 10mg 0.28 0.03 to 0.53 ADCS/ADL
Pooled 0.31 0.21 to 0.40
Galantamine
Brodaty et al., 2005 16-24mg 0.17 -0.02 to 0.35 ADCS/ADL
Brodaty et al., 2005 16-24mg (PRC) 0.30 0.11 to 0.49 ADCS/ADL
Rockwood et al., 2001 24-32mg 0.39 0.17 to 0.61 DAD
Tariot et al., 2000 16mg 0.37 0.12 to 0.61 ADCS/ADL
Tariot et al., 2000 24mg 0.24 0.00 to 0.48 ADCS/ADL
Wilcock et al., 2000 24mg 0.18 -0.05 to 0.42 DAD
Pooled 0.27 0.18 to 0.36
Rivastigmine
Agid et al., 1998 6mg 0.15 -0.17 to 0.47 NOSGER
Corey-Bloom et al., 1998 6-12mg 0.37 0.15 to 0.6 PDS
Rosler et al., 1999 6-12mg 0.19 -0.03 to 0.41 PDS
Pooled 0.26 0.11 to 0.40
-0.2 0.2 0.4 0.6 0.8 1
Standarized Mean Difference (SMD) in Functional Outcome Change from Baseline to Endpoint
95% CI
0
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Comparative evidence: 
Direct comparisons
Two trials directly compared donepezil with galantamine 
(Wilcock et al 2003; Jones et al 2004), and two trials 
(4 articles) directly compared donepezil with rivastigmine 
(Wilkinson et al 2002; Bullock et al 2005, 2006; Touchon 
et al 2006). Only one of the four comparative trials was 
double-blinded (Bullock et al 2005). Relevant outcome data 
are shown in Figure 5.
Donepezil vs. galantamine
Conﬂ  icting head-to-head evidence about the comparative 
efﬁ  cacy of donepezil and galantamine comes from two 
open-label trials; one 52-week trial (Wilcock et al 2003) 
and one 12-week trial (Jones et al 2004). The 52-week trial 
compared donepezil 10 mg/day to galantamine 24 mg/day in 
182 patients with mild to moderate dementia (Wilcock et al 
2003). Relevant outcome measures included the ADAS-cog 
(cognition), the BADLS (function), and the NPI (behavior). 
At endpoint, no statistically signiﬁ  cant differences between 
donepezil- and galantamine-treated participants were 
observed for cognition (ADAS-cog mean change −3.4 vs. −2.2, 
respectively), function (BADLS mean change 2.7 vs. 2.5, 
respectively), and behavior (values not reported). In contrast, 
a shorter 12-week trial compared ﬂ  exible doses of donepezil 
5–10 mg/day (once daily) and galantamine 8–24 mg/day 
(twice daily) in 120 patients with mild to moderate dementia 
(Jones et al 2004) and found statistically signiﬁ  cant differ-
ences in cognition (ADAS-cog mean change −4.7 vs. −2.3, 
respectively) and function (DAD mean change 1.6 vs. −0.4), 
favoring donepezil (P  0.05). The 12- and 52-week stud-
ies were both open-label, compromising their validity. Both 
trials compared relatively equivalent drug doses. However, 
participants in the 12-week study had less severe baseline 
MMSE scores than participants in the 52-week trial (mean 
baseline MMSE = 18 vs. 15, respectively). The 12-week trial 
was funded by the makers of donepezil, while the 52-week 
trial was funded by the makers of galantamine.
Donepezil vs. rivastigmine
Head-to-head evidence for the comparative efﬁ  cacy of 
donepezil and rivastigmine also is limited to two trials, with 
similarly conﬂ  icting results as the evidence for donepezil and 
galantamine. The strongest evidence comes from a good-
quality 2-year double-blinded randomized trial (Bullock 
et al 2005) that compared flexible doses of donepezil 
(5–10 mg/day) with ﬂ  exible doses of rivastigmine (3–12 
mg/day) in 994 participants with moderate to moderately-severe 
dementia. Donepezil- and rivastigmine-treated participants 
had similar changes in cognition (Severe Impairment Battery 
[SIB) mean change −9.9 vs. −9.3, respectively; P  0.05) 
and behavior (NPI mean change 2.4 vs. 2.9, respectively; 
P  0.05) over a 2-year period (Bullock et al 2005). How-
ever, rivastigmine-treated participants had statistically sig-
niﬁ  cantly better functional (ADCS-ADL −12.8 vs. −14.9, 
respectively; P  0.05) and global assessment outcomes 
(Global Deterioration Scale [GDS] 0.58 vs. 0.69, respec-
tively; P = 0.05) than donepezil-treated participants. 
Figure 3 Meta-analysis of behavior outcomes for active treatment compared with placebo.
Notes: aLimited to doses recommended by product labeling.
Abbreviations: WMD, Weighted Mean Difference; PRC, Prolonged Release Capsule; CI, Conﬁ  dence Interval; NPI, Neuropsychiatric Inventory.
Drug Daily Doseª WMD
Donepezil
AD2000 Collaborative, 2004 5-10mg -6.00 -8.61 to -3.39
Feldman et al., 2001 5-10mg -5.50 -9.14 to -1.86
Tariot et al., 2001 5-10mg -2.60 -7.87 to 2.67
Winblad et al., 2006 10mg -1.70 -4.75 to 1.35
Pooled -4.3 -5.95 to -2.65
Galantamine
Brodaty et al., 2005 16-24mg -1.50 -3.67 to 0.67
Brodaty et al., 2005 16-24mg (PRC) -1.20 -3.29 to 0.89
Rockwood et al., 2001 24-32mg -0.90 -2.69 to 0.89
Tariot et al., 2000 16mg -2.10 -4.48 to 0.28
Tariot et al., 2000 24mg -2.00 -4.50 to 0.50
Pooled -1.44 -2.39 to -0.48
-10 -8 -6 -4 -2 2
 Weighted Mean Difference (WMD) in NPI Change from Baseline to Endpoint
95% CI
0
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A shorter 12-week open-label trial (Wilkinson et al 2002) 
compared ﬂ  exible doses of donepezil (5–10 mg/day) with 
ﬂ  exible doses of rivastigmine (6–12 mg/day) in 111 patients 
with mild to moderate dementia and found no statistically 
significant differences in cognition (ADAS-cog mean 
change −0.9 vs. −1.1, respectively; P  0.05) at 12 weeks 
(Wilkinson et al 2002). Measures of function and behavior 
were not included in this shorter trial. Aside from apparent 
difference in duration of follow-up, the largest distinctions 
between the 12-week and 2-year trials are the double-blinded 
design (single- vs. double-blinded, respectively) and dif-
ferences in baseline severity of dementia (mean baseline 
MMSE = 21 vs. 15, respectively). The 12-week trial was 
funded by the makers of donepezil, while the 2-year trial 
was funded by the makers of rivastigmine.
Comparative evidence:   Adjusted indirect 
comparisons
Data were sufficient to conduct adjusted indirect com-
parisons of each drug for cognition (ADAS-cog) and global 
assessment of change (CIBIC+); data were not sufﬁ  cient 
to indirectly compare drugs with regard to function, and 
only donepezil and galantamine could be indirectly com-
pared with regard to behavior (Figure 5). Adjusted indirect 
comparison of ADAS-cog change from baseline to endpoint 
revealed no statistically signiﬁ  cant differences in the pooled 
weighted mean differences among drugs (P  0.05 for all 
comparisons). In other words, the drugs produced effects 
of similar magnitude when compared with placebo. How-
ever, adjusted indirect comparisons detected differences 
among drugs for behavior and global assessment of change. 
Behavior deteriorated less for donepezil compared with 
galantamine (P = 0.003); data were insufﬁ  cient to indi-
rectly compare donepezil with rivastigmine or galantamine 
with rivastigmine. The relative risk of being classiﬁ  ed as a 
global responder statistically signiﬁ  cantly favored donepezil 
and rivastigmine compared with galantamine (RR = 1.63 
[P  0.005] and 1.42 [P  0.05], respectively for comparison 
with galantamine), but did not statistically signiﬁ  cantly differ 
between donepezil and rivastigmine (P = 0.4).
Safety and tolerability
On average across all included trials, 76% (95% CI 70% to 
81%) of participants randomized to active treatment reported at 
least one adverse event. The most frequently reported adverse 
events were nausea (overall mean 19%; 95% CI 14% to 24%), 
vomiting (overall mean 13%; 95% CI 9% to 16%), diarrhea 
(overall mean 11%; 95% CI 9% to 12%), dizziness (overall 
Figure 4 Meta-analysis of clinical global assessment of change for active treatment compared with placebo.
Notes: aLimited to doses recommended by product labeling.
Abbreviations: RR, Relative Risk; PRC, Prolonged Release Capsule; CI, Conﬁ  dence Interval; CIBIC+, Clinician Interview-Based Impression of Change Incorporating Caregiver 
Information.
Drug Daily Doseª RR
Donepezil
Burns et al., 1999 5mg 1.52 0.94 to 2.44
Burns et al., 1999 10mg 1.80 1.13 to 2.86
Rogers et al., 1998a 5mg 1.71 1.01 to 2.88
Rogers et al., 1998a 10mg 2.00 1.20 to 3.34
Rogers et al., 1998b 5mg 2.63 1.29 to 5.35
Rogers et al., 1998b 10mg 2.52 1.23 to 5.13
Pooled 1.88 1.50 to 2.34
Galantamine
Brodaty et al., 2005 16-24mg 1.02 0.70 to 1.50
Brodaty et al., 2005 16-24mg (PRC) 1.08 0.74 to 1.58
Raskind et al., 2000 24mg 1.38 0.87 to 2.18
Rockwood et al., 2001 24-32mg 1.28 0.84 to 1.94
Wilcock et al., 2000 24mg 1.13 0.73 to 1.72
Pooled 1.15 0.96 to 1.39
Rivastigmine
Corey-Bloom et al., 1998 6-12mg 1.55 1.08 to 2.24
Rosler et al., 1999 6-12mg 1.71 1.25 to 2.35
Pooled 1.64 1.29 to 2.09
0.5 2 5
Relative Risk (RR) of Response on the CIBIC+ Global Assessment of Change
95% CI
1
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mean 10%; 95% CI 8% to 12%), and weight loss (overall mean 
9%; 95% CI 6% to 11%). With the exception of diarrhea (mean 
frequency: donepezil 12%; galantamine 8%; rivastigmine 
13%), the mean frequency of these events was consistently 
lowest for donepezil and highest for rivastigmine (nausea 11%, 
24%, and 44%; vomiting 7%, 14%, and 30%; dizziness 8%, 
10%, and 22%; and weight loss 7%, 10%, and 11%, respec-
tively for donepezil, galantamine, and rivastigmine).
Overall, 26% (95% CI 21% to 31%) of participants 
randomized to active treatment withdrew from trials, approxi-
mately half of which withdrew speciﬁ  cally because of adverse 
events (overall mean 13%; 95% CI 10% to 16%). The frequency 
of withdrawals and withdrawals due to adverse events also was 
lowest among donepezil trials and highest among rivastigmine 
trials. Withdrawals and withdrawals due to adverse events were 
24% (95% CI 16% to 32%) and 11% (95% CI 8% to 14%), 
respectively, for donepezil; 27% (95% CI 21% to 33%) and 
14% (95% CI 10% to 18%), respectively, for galantamine; and 
28% (95% CI 15% to 40%) and 21% (95% CI 12% to 31%), 
respectively, for rivastigmine. In our meta-analysis of placebo-
controlled trials, the pooled relative risk of withdrawing for any 
reason was 1.1 (95% CI 0.9 to 1.3) for donepezil, 1.6 (95% CI 1.3 
to 1.9) for galantamine, and 2.3 (95% CI 1.8 to 2.9) for rivastig-
mine. Similarly, the pooled relative risk of withdrawing because 
of adverse events was 1.3 (95% CI 0.9 to 1.8) for donepezil, 2.0 
(95% CI 1.4 to 2.8) for galantamine, and 3.6 (95% CI 2.6 to 5.1) 
for rivastigmine. These analyses included all placebo-controlled 
studies included in our assessment of efﬁ  cacy (Table 1), except 
for the AD2000 Collaborative Group study (2004) which did not 
report sufﬁ  cient data. Heterogeneity was moderate for analyses 
of donepezil and galantamine (I2 between 40% to 50% for all), 
but low (I2 = 0%) for analyses of rivastigmine. Factors such as 
drug dose and baseline disease severity varied among studies, 
and likely contributed to heterogeneity.
Discussion
Meta-analyses of placebo-controlled data support the drugs’ 
modest overall beneﬁ  ts for stabilizing or slowing decline in 
Figure 5 Comparative evidence for donepezil, galantamine, and rivastigminea.
Notes: aLimited to comparisons with sufﬁ  cient data for a single outcome measure and to doses recommended by product labeling.
Abbreviations : WMD, Weighted Mean Difference (reﬂ  ects the pooled difference for Drug A – Drug B); RR, Relative Risk (reﬂ  ects the relative risk of responding with Drug B/Drug A); 
CI, Conﬁ  dence Interval; ADAS-cog, Alzheimer’s Disease Assessment Scale-Cognitive section; NPI, Neuropsychiatric Inventory; CIBIC+, Clinician Interview-Based Impression 
of Change Incorporating Caregiver Information.
Cognition (Drug A vs Drug B) WMD
Direct Comparison
Donepezil vs. Galantamine (Jones 2004) -2.4 -4.47 to -0.33*
Donepezil vs. Galantamine (Wilcock 2003) 1.21 -0.97 to 3.39
Donepezil vs. Rivastigmine (Wilkinson 2002) 0.15 -1.56 to 1.86
Adjusted Indirect Comparison
Donepezil vs. Galantamine 0.09 -0.65 to 0.83
Donepezil vs. Rivastigmine 0.34 -0.66 to 1.34
Galantamine vs. Rivastigmine 0.25 -0.65 to 1.15
-6 -4 -2 2 4 6
Favors Drug A Favors Drug B
Behavior (Drug A vs Drug B) WMD
Direct Comparison
Donepezil vs. Rivastigmine (Bullock 2005) 0.54 -1.68 to 2.70
Adjusted Indirect Comparison
Donepezil vs. Galantamine -2.86 -4.77 to -0.95*
-6 -4 -2 2 4 6
Favors Drug A Favors Drug B
Global Assessment (Drug A vs Drug B) RR
Adjusted Indirect Comparison
Donepezil vs. Galantamine 0.61 0.49 to 0.82*
Donepezil vs. Rivastigmine 0.87 0.63 to 1.21
Galantamine vs. Rivastigmine 1.42 1.05 to 1.93*
0.5 2 5
Favors Drug A Favors Drug B
95% CI
95% CI
95% CI
1
Relative Risk (CIBIC+)
Weighted Mean Difference (NPI)
0
Weighted Mean Difference (ADAS-cog)
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cognition, function, behavior, and clinical global change. 
Evidence directly comparing one drug with another is limited 
to four trials, three of which used an open-label design. Of 
two open-label trials comparing donepezil with galantamine 
(Wilcock et al 2003; Jones et al 2004), one found no statisti-
cally signiﬁ  cant differences in efﬁ  cacy (Wilcock et al 2003), 
while one found statistically signiﬁ  cantly better cognition 
and function outcomes for donepezil (Jones et al 2004). 
One open-label trial (Wilkinson et al 2002) and one double-
blinded trial (Bullock et al 2005) directly compared donepezil 
with rivastigmine. Both trials found drugs to be similar with 
regard to cognitive outcomes, although the double-blinded 
study reported small but statistically signiﬁ  cant differences 
in function favoring rivastigmine compared with donepezil. 
Adjusted indirect comparisons found drugs to be similar with 
regard to cognitive outcomes. However, donepezil performed 
statistically signiﬁ  cantly better than galantamine with regard 
to behavior, and both donepezil and rivastigmine performed 
statistically signiﬁ  cantly better than galantamine with regard 
to global assessment.
Results of our adjusted indirect comparisons are consis-
tent with ﬁ  ndings of some head-to-head trials, but conﬂ  ict 
with results of other comparative studies. For example, our 
indirect comparison of cognitive outcomes did not reveal 
statistically signiﬁ  cant differences among drugs—a conclu-
sion similar to most comparative trials (Wilkinson et al 2002; 
Wilcock et al 2003; Bullock et al 2005) and a meta-analysis 
by Harry and Zakzanis (2005). However, Jones and col-
leagues (2004) reported greater improvements in cognition 
for donepezil- compared with galantamine-treated patients, 
a ﬁ  nding inconsistent with other evidence. Interestingly, our 
adjusted indirect comparisons paralleled the direction of the 
ﬁ  ndings of Jones and colleagues for other outcome measures, 
even though the Jones study (2004) did not measure these 
outcomes. For instance, our adjusted indirect comparison 
favored donepezil over galantamine for measures of behavior 
(NPI) and global assessment of change (CIBIC+). No other 
evidence directly comparing donepezil and galantamine on 
these outcome measures are available to contrast this ﬁ  nding. 
Although our adjusted indirect comparison found donepezil 
and rivastigmine to be similar with regard to clinical global 
assessment on the CIBIC+, a good-rated comparative trial 
found modest differences (P = 0.05) favoring rivastigmine 
over donepezil. However, the comparative trial was con-
ducted in patients with moderate to severe dementia and used 
the GDS rather than the CIBIC+ to assess global change. 
Thus, differences in measurement scale and trial population 
confound this comparison.
The most common adverse events reported in trials 
were nausea, vomiting, diarrhea, dizziness, and weight loss. 
Across studies, the frequency in which these events were 
reported was generally lowest for donepezil and highest for 
rivastigmine. This trend paralleled overall withdrawal rates 
and withdrawals due to adverse events. The relative risk of 
withdrawing for any reason or because of adverse events was 
similar for donepezil compared with placebo, but the relative 
risk was statistically signiﬁ  cantly greater for galantamine and 
rivastigmine compared with placebo.
Although the frequency in which adverse events were 
reported and analysis of withdrawal rates provide a compel-
ling argument in favor of donepezil with regard to toler-
ability, heterogeneity in these data must be considered. 
First, studies differ in how adverse events are assessed and 
reported. Most studies did not specify adverse a priori, and 
reporting of speciﬁ  c events varied (eg, report all events with 
incidence 5% vs. report events statistically signiﬁ  cantly 
different from placebo). Second, the frequency of speciﬁ  c 
events varied within individual studies and across studies for 
a given drug. Within study variance could be explained in 
part by differences in doses, with higher adverse event rates 
generally reported among higher doses (Ritchie et al 2004). In 
some cases, differences in event rates could be explained by 
differences in formulation. For example, one study of galan-
tamine compared the immediate release and the extended 
release formulation with placebo (Brodaty et al 2005). A 
post hoc comparison of these formulations (Dunbar et al 
2006) illustrated that patients randomized to the extended 
release formulation had statistically signiﬁ  cantly fewer days 
with nausea than participants randomized to the immediate 
release formulation (18% vs. 38%; P = 0.014).
Many different measurement scales are used in assess-
ing outcomes of Alzheimer’s treatment. We chose to focus 
on four overall outcome domains: cognition, function, 
behavior, and clinical global assessment of change. Within 
these general domains, we limited our data abstraction to 
speciﬁ  c measures that were commonly used across trials. For 
example, we abstracted data only for the ADAS-cog scale for 
cognition. Although this is a relatively common scale used 
to assess cognition in trials of mild to moderate dementia, 
its use in patients with more severe dementia is subject to 
ﬂ  oor effects (Schmitt et al 2006). Measurement scales have 
been developed for use in patients with more severe dementia 
(eg, the SIB), but the number of trials conducted in patients 
with severe dementia and using these scales were too few for 
us to pool data. We chose to exclude studies that did not use 
predeﬁ  ned outcome measures, thus indirectly limiting our Clinical Interventions in Aging 2008:3(2) 222
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analysis to populations with mild to moderate dementia—at 
least for some outcome domains. For function, because 
measurement scales were so extensively varied, we used 
a standardized effect size analysis. This analysis included 
measures believed to be sensitive in more severe disease 
(eg, the ADCS-ADL [Galasko et al 1997] and DAD [Gelinas 
et al 1999]), but it is subject to other limitations such as 
interpretation of meaningful differences (Cohen 1988). 
As additional evidence accrues for speciﬁ  c measurement 
scales, additional meta-analyses should test the sensitivity of 
our ﬁ  ndings among patients with more severe disease.
A number of other factors limit the conclusions of our 
analysis. First, Alzheimer’s disease is progressive, and 
patients decline at different rates. This may have implications 
when pooling data across studies. For example, one study 
conducted in patients with early-stage Alzheimer’s disease 
illustrated little or no decline in cognition among the placebo-
treated participants (Seltzer et al 2004), while a second study 
reported nearly a 2-point decline in cognition (ADAS-cog) 
among placebo-treated participants with mild-to-moderate 
dementia (Rogers et al 1998b). In our analysis, we pooled 
data from all studies regardless of dementia severity, poten-
tially biasing our results. Second, although we limited our 
review to doses within the manufacturers’ current recom-
mendations, we still included a range of ﬁ  xed and ﬂ  exible 
doses. A meta-analysis by Ritchie and colleagues (2004) 
demonstrated the dose-response relationship for these drugs 
by pooling studies for speciﬁ  c doses. Although we present 
only the overall analysis for each outcome measure, we also 
conducted dose-stratiﬁ  ed sensitivity analyses. Stratifying 
by dose illustrated a dose-response relationship, but did not 
change conclusions of individual meta-analyses or indirect 
comparisons. Other population inclusion and exclusion 
criteria might also inﬂ  uence our results. Although most 
trials used accepted methods for conﬁ  rming the diagnosis 
of Alzheimer’s (eg, diagnosis consistent with the DSM-IV 
and the National Institute of Neurological and Communica-
tive Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria), studies 
did not consistently include or exclude patients who also had 
symptoms suggestive of concomitant Lewy body disease, 
patients with other co-morbid diagnoses, or patients using 
other medications. The implications of these distinctions 
may be signiﬁ  cant. For example, a large prospective cohort 
study found that patients without concomitant disease at 
baseline had a 2-fold greater likelihood of being classiﬁ  ed 
as a cognitive responder at 9 months (Raschetti et al 2005). 
Arguably, however, factors such as co-morbid illness and 
variations in other medication use are representative of the 
environment for treating Alzheimer’s disease. Still, in the 
context of meta-analysis, variation in patient populations 
and trial design can bias conclusions. This potential concern 
is likely reﬂ  ected by the moderate to high heterogeneity we 
detected in some meta-analyses.
Finally, our analysis was limited to studies identiﬁ  ed at 
the time of our literature search (ie, July 2007). New evi-
dence continues to accrue and should be considered in future 
reviews. For example, a recent trial (Howard et al 2007) 
compared donepezil to placebo in patients with Alzheimer’s 
disease who had clinically signiﬁ  cant agitation. Donepezil 
was not more effective than placebo in treating agitation or 
other behavioral symptoms, even though cognitive mea-
sures showed modest beneﬁ  t from donepezil compared with 
placebo. If included, these ﬁ  ndings may have inﬂ  uenced 
conclusions of our adjusted indirect comparisons.
Conclusions
Compared with placebo, the cholinesterase inhibitors 
donepezil, galantamine, and rivastigmine are able to stabilize 
or slow decline in cognition, function, behavior, and global 
change. No clear evidence exists to determine whether one of 
these drugs is more efﬁ  cacious than another, although adjusted 
indirect comparisons suggest that donepezil and rivastigmine 
may be slightly more efﬁ  cacious than galantamine, at least as 
reﬂ  ected by some outcome measures. The incidence of com-
mon adverse events appears to be lowest with donepezil and 
highest with rivastigmine. Additional high quality compara-
tive evidence is needed to conﬁ  rm these conclusions.
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